Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,866.40 | 69.10 | -0.77% |
| CAC 40 | 8,244.29 | 0.00 | 0.00% |
| DAX 40 | 24,944.95 | 149.01 | 0.60% |
| Dow JONES (US) | 51,561.93 | 874.86 | 1.73% |
| FTSE 100 | 10,360.32 | 28.02 | 0.27% |
| HKSE | 25,127.69 | 125.71 | -0.50% |
| NASDAQ | 26,830.96 | 23.02 | -0.09% |
| Nikkei 225 | 66,331.86 | 1,138.83 | -1.69% |
| NZX 50 Index | 13,124.54 | 22.93 | 0.18% |
| S&P 500 | 7,584.31 | 30.63 | 0.41% |
| S&P/ASX 200 | 8,635.10 | 70.00 | -0.80% |
| SSE Composite Index | 4,050.56 | 7.22 | -0.18% |